- Sections :
- Crime & Public Safety
- Restaurants & Food
- Sports
- More
Power3 Appoints Dr. Sabbagh to Scientific Advisory Board
The Woodlands, TX -- Power3 Medical Products, Inc. (OTCBB: PWRM), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, appointed Dr. Marwan N. Sabbagh to the Company’s Scientific Advisory Board. Dr. Sabbagh, a national leader in neurodegenerative disease, will collaborate with Power3 Medical in a validation study of blood serum patient samples using Power3’s NuroPro® diagnostic screening test.
Dr. Sabbagh is currently the Director of Clinical Research at the Cleo Roberts Center of Clinical Research at the Sun Health Research Institute located in Sun City, Arizona. Dr. Sabbagh has been published in seventy reviews, and has written original research articles on Alzheimer’s disease and dementia.
Additionally, he has written a soon to be published book on Alzheimer’s prevention. Dr. Sabbagh received his medical degree from the University of Arizona in Tucson and completed his residency in Neurology at Baylor College of Medicine in Houston, and his fellowship at the University of California, San Diego School of Medicine. He also serves as the staff physician at Sun Health Boswell Hospital where he practices general neurology and specializes in the diagnosis and treatment of Alzheimer’s disease. Dr. Sabbagh is a Clinical Instructor in Neurology and provides both clinical and didactic expertise for the geriatric fellowship program.
“Sun Health Research Institute is a leader, nationally and internationally, in the effort to find answers to disorders related to aging, and Dr. Sabbagh’s vast experience and commitment in the field of neurodegenerative research is a tremendous asset to Power3’s Scientific Advisory Board,” Steve Rash, Chief Executive Officer of Power3 Medical commented. “The Cleo Roberts Center of Clinical Research has shown remarkable dedication to finding an early detection test and treatment for neurodegenerative diseases under Dr. Sabbagh’s guidance.”
Dr. Sabbagh adds, “I am very grateful for the opportunity to serve on Power3’s Scientific Advisory Board. I am looking forward to working with Power3’s innovative NuroPro test in its final validation studies before commercialization. I believe NuroPro has the ability to empower the medical community to improve patient treatment and to fight neurodegenerative diseases.”
About Sun Health Research Institute
For twenty-one years, Sun Health Research Institute has been a leader nationally and internationally in the effort to find answers to disorders of aging including Alzheimer’s disease, Parkinson’s disease, arthritis, and prostate cancer. The institute, together with its Arizona Alzheimer’s Consortium partners, has been designated by the National Institutes of Health as one of just twenty-nine Alzheimer’s Disease Centers in the nation. The institute’s Cleo Roberts Center for Clinical Research takes laboratory discoveries to clinical trials that foster hope for new treatments. Sun Health Research Institute is affiliated with the Sun Health non-profit community healthcare network.
About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BCSera-Pro, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas, and recently announced an agreement forming a joint venture (CRO) with NeoGenomics, Inc. (NASDAQ: NGNM - News) of Fort Myers, Florida, to commercialize Power3’s portfolio of IP, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s and Parkinson’s Diseases.